Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

Journal: Research and practice in thrombosis and haemostasis
Published Date: Dec 29, 2023

Abstract

BACKGROUND: Emicizumab is a bispecific antibody that bridges activated factor (F)IX and FX, mimicking the function of missing activated FVIII and thus improving hemostasis in people with hemophilia A. The efficacy and safety of emicizumab were demonstrated in 4 phase III clinical trials (HAVEN 1-4).

Authors

  • Anna Kiialainen
    F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Joanne I Adamkewicz
    Genentech, Inc, South San Francisco, California, USA.
  • Claire Petry
    F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Johannes Oldenburg
    University of Bonn, Bonn, Germany.
  • Steven W Pipe
    University of Michigan, Ann Arbor, Michigan, USA.
  • Guy Young
    Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Johnny Mahlangu
    University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
  • Michaela Lehle
    F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Markus Niggli
    F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Giancarlo Castaman
    Careggi University Hospital, Florence, Italy.
  • Víctor Jiménez-Yuste
    Department of Hematology, La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain.
  • Midori Shima
    Nara Medical University, Kashihara, Japan.
  • Claude Négrier
    Louis Pradel University Hospital, Lyon, France.
  • Christophe Schmitt
    F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals